Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AstraZeneca Pharma IndiaNSE:ASTRAZEN +1.24%86 Days Sales Outstanding is 28.56 as of Jun. 2026, which is 20% below its 10-year median of 35.88. GuruFocus rates NSE:ASTRAZEN with a GF Score™ of 86/100 and a GF Value™ of ₹11,579.81 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 947 Drug Manufacturers companies, AstraZeneca Pharma India ranks better than 89.76% on this metric.
The historical rank and industry rank for AstraZeneca Pharma India's Days Sales Outstanding or its related term are showing as below:
NSE:ASTRAZEN'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.96 Med: 35.88 Max: 42.07
Current: 30.96
During the past 13 years, AstraZeneca Pharma India's highest Days Sales Outstanding was 42.07. The lowest was 30.96. And the median was 35.88.
NSE:ASTRAZEN's Days Sales Outstanding is ranked better than 89.76% of 947
companies
in the Drug Manufacturers industry
Industry Median: 71.98
vs NSE:ASTRAZEN: 30.96
AstraZeneca Pharma India's Days Sales Outstanding
declined
from Jun. 2025 (32.05) to Jun. 2026 (28.56).
AstraZeneca Pharma India (NSE:ASTRAZEN) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
AstraZeneca Pharma India Days Sales Outstanding Related Terms
AstraZeneca Pharma India Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for AstraZeneca Pharma India's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca Pharma India Days Sales Outstanding Chart
NSE:ASTRAZEN vs ZTS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's Days Sales Outstanding falls into.
AstraZeneca Pharma India Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca Pharma India (NSE:ASTRAZEN) has a Days Sales Outstanding of 28.56 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on AstraZeneca Pharma India and its competitors. This is 20% below median its historical median of 35.88. Over the past decade, AstraZeneca Pharma India's Days Sales Outstanding has ranged from 30.96 to 42.07. According to the industry distribution chart, AstraZeneca Pharma India ranks #97 out of 947 companies in the Drug Manufacturers industry, placing it in the top 10.2%.
Is AstraZeneca Pharma India's Days Sales Outstanding too high?
AstraZeneca Pharma India's current Days Sales Outstanding of 28.56 is 20% below median its 10-year median of 35.88. Over the past 10 years, this metric has ranged from a low of 30.96 to a high of 42.07. The Drug Manufacturers industry median Days Sales Outstanding is 71.98. AstraZeneca Pharma India's value of 28.56 is 60.3% below this industry median. Based on the distribution chart, AstraZeneca Pharma India ranks #97 out of 947 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AstraZeneca Pharma India has a GF Score™ of 86/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #97 out of 947 companies for Days Sales Outstanding. This places AstraZeneca Pharma India in the top 10% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 71.98. AstraZeneca Pharma India's value of 28.56 is 60.3% below this benchmark. Historically, AstraZeneca Pharma India's own Days Sales Outstanding has ranged from 30.96 to 42.07 over the past decade. While the company's 10-year median is 35.88 vs. the industry median of 71.98, AstraZeneca Pharma India has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca Pharma India's current Days Sales Outstanding of 28.56 is 60.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on AstraZeneca Pharma India and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current Days Sales Outstanding is 28.56, which is 20% below median its own 10-year median of 35.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Possible Value Trap. The stock's GF Value™ is ₹11,579.81, compared to a current price of ₹6,751.50 — trading 41.7% below its estimated fair value. The current Days Sales Outstanding is 28.56, which is 20% below median its 10-year median of 35.88 and 60.3% below the Drug Manufacturers industry median of 71.98. AstraZeneca Pharma India's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current Days Sales Outstanding is 28.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹6,751.50 is trading 41.7% below its estimated GF Value™ of ₹11,579.81.
GuruFocus considers AstraZeneca Pharma India to be Possible Value Trap.
Key valuation signals for NSE:ASTRAZEN:
Days Sales Outstanding: 28.56 (20% below median its 10-year median of 35.88)
GF Value™: ₹11,579.81 vs. price of ₹6,751.50 (41.7% below fair value)
Industry Position: 60.3% below the Drug Manufacturers median (#97 of 947)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
86GF Score
Get the complete analysis for NSE:ASTRAZEN
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
